data_2jzh_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2jzh _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.66 HD22 ' HZ2' ' A' ' 109' ' ' LYS . 6.9 m-20 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.475 -0.565 . . . . 6.07 109.475 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -81.46 36.01 0.42 Allowed 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.435 -0.95 . . . . 3.86 108.435 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.461 ' H ' ' C ' ' A' ' 9' ' ' ASN . 63.7 m-85 -118.22 -134.77 0.33 Allowed 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.751 -0.593 . . . . 1.97 109.505 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.4 ' SD ' ' HB ' ' A' ' 90' ' ' VAL . 6.6 ttm -63.63 150.09 45.0 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.04 -1.038 . . . . 2.86 110.73 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 91.0 t -112.02 116.07 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.462 -0.774 . . . . 1.08 109.029 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.405 HD12 HG21 ' A' ' 14' ' ' ILE . 98.1 mt -73.6 104.26 2.4 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.355 -0.841 . . . . 1.05 108.955 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.56 -34.56 79.14 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.933 -1.667 . . . . 0.23 108.933 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 39.1 tp -171.94 147.53 2.17 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 118.845 -1.142 . . . . 1.09 110.719 179.018 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -117.43 104.42 11.08 Favored 'General case' 0 N--CA 1.496 1.848 0 N-CA-C 108.865 -0.791 . . . . 1.03 108.865 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.463 ' NH1' ' CG1' ' A' ' 28' ' ' VAL . 51.8 ttp180 -108.27 128.29 54.6 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 122.159 0.98 . . . . 3.69 112.104 -177.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 89.3 mt -95.99 127.5 48.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.782 -0.821 . . . . 1.04 108.782 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.582 ' OD2' ' NE2' ' A' ' 25' ' ' HIS . 67.1 t0 -163.74 115.33 1.39 Allowed 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 120.039 -0.664 . . . . 0.51 109.922 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.08 -10.0 12.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.136 -0.978 . . . . 2.09 109.773 -179.548 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 95.1 mtt180 -100.58 -2.84 31.85 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.89 -1.131 . . . . 3.47 110.554 -179.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 55.6 mt 59.02 -101.35 0.12 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.14 -0.975 . . . . 1.07 109.705 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 96.5 mt -101.49 124.45 55.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.343 -0.848 . . . . 1.06 109.263 179.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.582 ' NE2' ' OD2' ' A' ' 20' ' ' ASP . 5.8 p80 -150.23 140.07 21.83 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.876 -1.14 . . . . 0.62 110.006 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 54.96 -153.23 11.35 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.781 -1.328 . . . . 0.37 109.781 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -91.26 11.66 22.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.531 -0.982 . . . . 1.53 108.935 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.463 ' CG1' ' NH1' ' A' ' 18' ' ' ARG . 85.2 t -60.19 -44.58 95.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.516 -0.74 . . . . 1.12 109.585 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.456 ' O ' ' OG1' ' A' ' 33' ' ' THR . . . -73.46 -34.68 65.5 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 121.156 -0.965 . . . . 1.09 109.896 179.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.5 m -67.43 -53.91 24.92 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 119.862 -0.735 . . . . 1.09 109.917 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -64.22 -44.61 91.39 Favored 'General case' 0 N--CA 1.496 1.839 0 CA-C-O 121.364 0.602 . . . . 3.63 110.927 -178.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.485 ' O ' ' OG1' ' A' ' 36' ' ' THR . 24.3 m95 -67.09 -32.4 73.53 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.401 -0.812 . . . . 1.1 110.368 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 29' ' ' ALA . 82.6 m -65.57 -45.96 81.28 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.814 -1.179 . . . . 1.07 110.034 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 81.6 tttt -69.11 -42.27 76.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.206 -0.934 . . . . 2.51 110.324 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -69.0 -39.25 79.43 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.949 -1.094 . . . . 2.52 109.471 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.485 ' OG1' ' O ' ' A' ' 32' ' ' TRP . 73.7 p -80.18 -0.46 36.23 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.101 -1.0 . . . . 1.09 109.64 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 51.54 47.7 24.32 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.939 -1.101 . . . . 2.53 108.447 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.434 ' CG1' ' O ' ' A' ' 40' ' ' ARG . 55.5 t -105.09 133.54 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.07 -1.019 . . . . 1.72 109.68 -178.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 95.3 p -110.58 -5.06 15.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 107.81 -1.181 . . . . 1.85 107.81 178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.434 ' O ' ' CG1' ' A' ' 38' ' ' VAL . 0.1 OUTLIER -137.18 140.37 41.75 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.86 0.838 . . . . 3.45 111.025 -179.201 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.8 mt -133.1 127.52 54.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.395 -0.965 . . . . 1.04 108.395 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 97.9 mt -116.42 129.67 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.279 -0.888 . . . . 1.04 109.653 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 53.5 t -99.63 129.18 50.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.879 -0.786 . . . . 1.12 108.879 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.0 t -111.91 103.97 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.578 -0.701 . . . . 1.08 109.6 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 42.0 t -167.28 124.65 1.22 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.112 -0.992 . . . . 1.79 108.969 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -72.87 -35.13 67.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.412 -0.805 . . . . 0.71 110.339 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.19 -44.67 87.68 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.277 -0.89 . . . . 2.19 109.767 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 79.3 t -70.49 -43.23 78.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.136 -0.977 . . . . 1.06 109.543 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.68 -25.83 60.82 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.384 -0.823 . . . . 1.05 109.117 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.64 -5.39 59.17 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.188 -0.945 . . . . 1.05 109.36 179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -102.92 96.0 6.53 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.015 -1.053 . . . . 0.33 109.386 179.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 17.5 p -65.73 -32.45 74.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.319 -0.863 . . . . 1.92 110.537 -179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.56 -46.67 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.81 -1.181 . . . . 1.05 110.494 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 -64.56 -40.49 95.66 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.096 -1.002 . . . . 2.87 109.443 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 78.6 tttt -59.01 -42.39 90.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.218 -0.926 . . . . 2.22 109.646 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 97.8 m -61.6 -47.67 84.4 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 119.304 -0.958 . . . . 1.07 109.433 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 56.0 mt -62.96 -43.58 98.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.159 -0.963 . . . . 1.13 110.602 -178.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 82.2 mt -64.63 -41.29 96.25 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.782 -1.199 . . . . 1.08 109.502 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 34.0 p -69.28 -32.57 71.84 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.189 -0.945 . . . . 1.08 110.002 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 71.3 mt-30 -80.36 -15.82 55.97 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.601 -1.312 . . . . 2.32 110.853 -179.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 20.4 m -109.04 17.37 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 120.884 -1.135 . . . . 1.14 109.082 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.18 124.63 84.71 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.314 -0.867 . . . . 1.08 109.095 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -44.9 146.03 2.64 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.905 1.737 . . . . 0.9 112.126 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -55.18 133.59 58.98 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 C-N-CA 122.137 1.891 . . . . 0.66 112.258 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.64 -7.65 47.37 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 110.162 -1.175 . . . . 0.23 110.162 178.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.7 t -113.06 134.92 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -1.14 . . . . 1.32 109.277 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.03 134.94 47.29 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.401 -0.812 . . . . 1.82 109.072 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -111.3 133.22 53.79 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.967 -1.123 . . . . 1.03 107.967 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -122.86 155.32 36.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.529 -0.732 . . . . 0.29 110.096 -179.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 46.6 t -127.47 118.09 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.892 -0.781 . . . . 1.04 108.892 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 m -139.23 165.38 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.497 -0.752 . . . . 1.04 109.703 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.581 ' OD1' ' N ' ' A' ' 72' ' ' ASP . 6.2 p-10 -94.96 167.77 11.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.4 -0.813 . . . . 1.11 109.186 178.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 76.0 t -56.79 -45.14 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.187 -0.945 . . . . 1.05 109.845 -177.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.504 ' O ' HG21 ' A' ' 77' ' ' ILE . . . -61.6 -42.52 98.99 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.982 -1.074 . . . . 1.05 109.616 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 72.1 tttt -73.18 -33.76 65.62 Favored 'General case' 0 C--N 1.294 -1.839 0 O-C-N 120.371 -1.456 . . . . 2.49 111.149 -178.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 12.7 tpt -62.04 -39.07 91.07 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.551 -1.343 . . . . 1.48 110.128 -179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.513 HG21 ' N ' ' A' ' 78' ' ' ARG . 16.6 tt -61.74 -36.71 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.262 -0.899 . . . . 1.18 108.719 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . 0.513 ' N ' HG21 ' A' ' 77' ' ' ILE . 15.1 mtt180 -72.45 -38.26 68.32 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.156 -0.965 . . . . 4.18 110.631 179.321 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 95.5 t -62.69 -42.31 95.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 120.947 -1.096 . . . . 1.06 108.051 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -67.35 -30.85 70.78 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.036 -1.04 . . . . 1.07 109.762 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -74.26 6.96 3.11 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.212 -0.93 . . . . 1.03 110.032 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.421 ' C ' ' H ' ' A' ' 84' ' ' LYS . 64.4 t-20 -109.41 112.89 58.86 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.195 -0.94 . . . . 0.67 109.558 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -60.98 -0.54 1.24 Allowed 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 121.707 1.605 . . . . 1.06 111.915 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.421 ' H ' ' C ' ' A' ' 82' ' ' ASN . 88.5 tttt -61.94 -22.95 66.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -0.958 . . . . 2.13 109.467 179.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -105.9 13.98 28.68 Favored 'General case' 0 N--CA 1.492 1.67 0 C-N-CA 119.657 -0.817 . . . . 1.17 109.144 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.433 ' C ' ' H ' ' A' ' 88' ' ' GLU . . . -52.92 134.9 37.3 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.026 -1.046 . . . . 1.06 110.622 -178.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 78.27 -33.21 1.78 Allowed Glycine 0 N--CA 1.487 2.063 0 N-CA-C 109.38 -1.488 . . . . 0.26 109.38 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . 0.433 ' H ' ' C ' ' A' ' 86' ' ' ALA . 26.1 tp10 -52.88 137.22 32.71 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.268 -1.137 . . . . 2.18 109.601 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 53.7 mtt180 -96.9 119.03 34.62 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.224 -0.923 . . . . 3.7 109.418 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.4 ' HB ' ' SD ' ' A' ' 12' ' ' MET . 91.1 t -124.76 143.06 39.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 CA-C-O 121.885 0.85 . . . . 1.15 110.883 -177.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 12.8 ttp -102.53 135.15 44.67 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.368 -0.975 . . . . 2.18 108.368 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 61.0 mt -101.12 128.05 47.38 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.61 -0.836 . . . . 1.04 110.221 -178.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 94.9 mt -109.27 125.6 52.46 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.844 0.831 . . . . 1.21 109.016 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -126.39 161.88 26.84 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.645 0.736 . . . . 0.18 109.805 -178.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 69.3 p -108.93 -20.42 13.05 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.459 -0.941 . . . . 1.05 108.459 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . 0.476 ' OD1' ' O ' ' A' ' 96' ' ' ASN . 20.5 p30 -150.89 141.6 14.76 Favored Pre-proline 0 N--CA 1.489 1.475 0 O-C-N 121.67 -0.644 . . . . 1.67 109.784 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -62.56 -12.62 29.01 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 122.498 2.132 . . . . 0.66 112.029 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 98.4 m -64.41 -42.79 95.86 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.394 -0.965 . . . . 1.07 108.394 177.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -68.24 -23.74 64.83 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.548 -0.72 . . . . 0.37 110.219 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 99.6 t -72.29 -43.72 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.068 -1.02 . . . . 1.06 109.439 178.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -63.59 -35.01 79.11 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.409 -0.916 . . . . 1.94 108.799 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 89.7 mtt180 -62.95 -42.4 99.8 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.193 -1.003 . . . . 3.52 110.061 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 3.2 mp -64.8 -40.17 94.79 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 117.783 -1.567 . . . . 1.76 108.913 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 83.4 t -61.57 -45.14 99.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 120.766 -1.209 . . . . 1.06 109.107 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -59.17 -30.06 67.9 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.97 -1.081 . . . . 2.44 109.533 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -76.42 2.99 55.84 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.886 -1.286 . . . . 0.26 109.886 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.53 15.16 47.92 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 110.154 -1.179 . . . . 0.23 110.154 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 97.4 t -78.11 138.56 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 107.185 -1.413 . . . . 1.06 107.185 177.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.66 ' HZ2' HD22 ' A' ' 9' ' ' ASN . 56.1 tttt -95.62 120.95 36.76 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.249 -0.907 . . . . 3.4 111.369 -177.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 98.1 mt -129.81 124.96 59.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.375 -0.828 . . . . 1.03 108.804 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 37.5 p -92.45 -30.15 15.89 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.771 -1.206 . . . . 1.15 110.479 -178.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 22.0 m -156.58 151.19 25.71 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.008 -1.057 . . . . 0.83 109.986 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.2 t -122.92 134.46 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 N-CA-C 109.08 -0.711 . . . . 1.04 109.08 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . 0.472 ' ND2' ' CH2' ' A' ' 32' ' ' TRP . 37.8 t30 -108.43 127.5 53.95 Favored 'General case' 0 N--CA 1.488 1.44 0 CA-C-O 121.687 0.756 . . . . 1.9 110.629 -178.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 3.4 t -90.33 108.17 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 C-N-CA 119.955 -0.698 . . . . 1.04 109.195 179.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -81.05 -52.77 4.17 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.874 -1.29 . . . . 0.15 109.874 -179.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -174.18 153.29 16.39 Favored Glycine 0 N--CA 1.49 2.279 0 C-N-CA 118.785 -1.674 . . . . 0.18 111.266 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' MET . . . . . 0.405 ' HB2' ' H ' ' A' ' 132' ' ' SER . 98.6 mtp -143.39 117.97 9.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.671 -0.899 . . . . 1.04 109.823 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -52.07 129.07 26.45 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.343 -0.848 . . . . 1.07 109.492 -179.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.664 ' CD1' ' N ' ' A' ' 121' ' ' ARG . 11.9 t80 -71.12 161.1 31.69 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.306 -0.871 . . . . 0.61 109.463 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.664 ' N ' ' CD1' ' A' ' 120' ' ' PHE . 10.1 ttm180 -160.56 159.93 31.2 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.13 -0.981 . . . . 3.82 108.914 178.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 55.0 tt0 -65.74 138.58 58.04 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.883 -1.135 . . . . 2.63 110.725 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.74 -12.91 65.8 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.053 -1.619 . . . . 0.24 109.053 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -100.56 162.4 12.96 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.338 -1.095 . . . . 2.11 109.371 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 23.6 m -108.98 135.21 50.53 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.507 -0.923 . . . . 1.03 108.507 179.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -79.83 117.43 20.69 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 120.974 -1.079 . . . . 1.72 110.108 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 128' ' ' ASN . 26.7 m -96.68 -28.75 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 N-CA-C 108.942 -0.762 . . . . 1.17 108.942 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.406 ' N ' HG22 ' A' ' 127' ' ' VAL . 6.3 t-20 -139.04 -177.09 4.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.269 -0.894 . . . . 1.25 109.923 -179.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 65.2 m-20 -58.22 -29.73 65.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.535 -0.728 . . . . 2.8 110.864 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -145.5 24.38 1.4 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.793 -1.192 . . . . 1.06 109.775 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 60.3 t -118.95 119.66 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 CA-C-O 121.968 0.889 . . . . 1.04 109.39 179.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.405 ' H ' ' HB2' ' A' ' 118' ' ' MET . 40.5 m -117.35 147.34 42.71 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.388 0.613 . . . . 0.95 109.404 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 12.7 m -135.99 137.96 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 CA-C-O 122.017 0.913 . . . . 1.05 110.746 -179.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . 0.441 ' OD1' ' CG ' ' A' ' 137' ' ' ASP . 32.2 p-10 -104.58 171.2 7.46 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.115 -1.439 . . . . 0.57 107.115 178.001 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -57.68 -23.15 49.99 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.721 -1.237 . . . . 2.16 109.556 -179.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -79.52 -43.07 23.82 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.154 -0.966 . . . . 2.36 109.691 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . 0.441 ' CG ' ' OD1' ' A' ' 134' ' ' ASP . 98.1 m-20 -63.72 -41.5 98.06 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.267 -0.895 . . . . 0.21 108.703 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 95.8 mt -62.13 -45.59 98.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 108.794 -0.817 . . . . 1.04 108.794 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -57.73 -38.36 75.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.939 -1.101 . . . . 2.3 110.503 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.59 -40.77 84.79 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.605 -1.31 . . . . 1.04 109.772 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -64.51 -40.11 95.03 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.37 -0.831 . . . . 0.23 110.019 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 71.3 mttt -63.78 -39.54 94.51 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.945 -1.097 . . . . 2.52 110.488 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 33.1 mttt -66.78 -41.19 88.08 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.044 -1.035 . . . . 2.27 110.14 -179.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 55.9 mt -62.75 -42.18 99.55 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.844 -1.169 . . . . 1.08 107.844 179.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . 0.535 HD21 ' HG3' ' A' ' 165' ' ' MET . 35.7 t-20 -63.63 -40.24 96.37 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.275 -0.891 . . . . 1.88 109.458 179.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -62.61 -22.55 66.49 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.088 -1.008 . . . . 1.04 109.379 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 77.0 mtt-85 -88.54 7.32 33.71 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.051 -1.03 . . . . 2.96 109.674 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 82.38 12.6 80.26 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.801 -1.319 . . . . 0.18 109.801 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 96.0 mt -85.88 135.18 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.076 -1.25 . . . . 1.04 109.449 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -81.99 141.25 33.43 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.406 -0.809 . . . . 2.44 110.886 -179.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 61.0 mt -123.47 111.55 16.45 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.034 -0.728 . . . . 1.04 109.034 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -115.28 139.86 49.6 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.352 -0.842 . . . . 2.14 110.33 -179.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.606 ' CG2' ' SD ' ' A' ' 164' ' ' MET . 48.8 t -111.03 123.86 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 108.99 -0.745 . . . . 1.05 108.99 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.455 ' HE ' ' ND2' ' A' ' 114' ' ' ASN . 31.2 ptt180 -164.74 137.44 4.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.221 -0.924 . . . . 3.65 110.899 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -80.63 -45.29 17.51 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.233 -0.917 . . . . 2.29 109.776 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 25.6 m -129.74 154.05 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.152 -0.968 . . . . 1.09 109.015 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 4.2 p -65.26 -15.84 62.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.905 -1.122 . . . . 1.64 109.591 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 50.1 p -86.17 -9.11 57.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.014 -1.054 . . . . 1.17 109.528 -179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -92.59 150.27 39.5 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.167 -0.958 . . . . 0.45 109.497 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -55.65 141.03 84.49 Favored 'Trans proline' 0 N--CA 1.493 1.445 0 C-N-CA 121.772 1.648 . . . . 0.52 111.458 179.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 8.3 mttt -84.84 134.75 34.28 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.923 -1.11 . . . . 3.2 109.698 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 87.8 mt -114.77 153.31 30.57 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.51 -1.293 . . . . 1.06 107.51 178.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -90.34 130.97 36.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.662 -1.274 . . . . 2.56 109.538 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.606 ' SD ' ' CG2' ' A' ' 153' ' ' VAL . 8.0 tpt -56.78 -44.22 81.63 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.565 -0.709 . . . . 1.4 109.414 -178.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' MET . . . . . 0.535 ' HG3' HD21 ' A' ' 145' ' ' ASN . 93.7 mmm -60.76 -41.16 94.89 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.109 -0.994 . . . . 1.91 109.649 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -60.91 -43.66 98.23 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.414 -0.804 . . . . 0.28 110.001 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 93.0 mt -65.61 -41.79 92.33 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.213 -0.929 . . . . 1.05 109.5 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 95.9 mt -75.99 -25.08 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.448 -0.783 . . . . 1.06 109.544 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -71.56 -30.54 66.0 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.279 -1.513 . . . . 1.83 109.684 179.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 94.4 mttt -84.23 -6.25 59.37 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 119.197 -1.001 . . . . 2.59 109.37 -179.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' ILE . . . . . . . . . . . . . 97.1 mt -109.07 -66.1 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 105.842 -1.91 . . . . 1.38 105.842 176.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -81.97 140.69 33.85 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 106.803 -1.554 . . . . 2.1 106.803 177.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.749 ' CB ' ' HZ3' ' A' ' 173' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.286 -2.167 0 C-N-CA 119.44 -0.904 . . . . 7.1 108.723 -179.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.928 HD22 ' HD2' ' A' ' 109' ' ' LYS . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.475 -0.565 . . . . 5.52 109.475 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -81.46 36.01 0.42 Allowed 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.435 -0.95 . . . . 3.86 108.435 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.422 ' H ' ' C ' ' A' ' 9' ' ' ASN . 63.7 m-85 -118.22 -134.77 0.33 Allowed 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.751 -0.593 . . . . 1.51 109.505 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.419 ' SD ' ' HB ' ' A' ' 90' ' ' VAL . 6.6 ttm -63.63 150.09 45.0 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.04 -1.038 . . . . 2.44 110.73 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 91.0 t -112.02 116.07 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.462 -0.774 . . . . 0.33 109.029 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 98.1 mt -73.6 104.26 2.4 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.355 -0.841 . . . . 0.22 108.955 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.56 -34.56 79.14 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.933 -1.667 . . . . 0.19 108.933 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 39.1 tp -171.94 147.53 2.17 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 118.845 -1.142 . . . . 0.32 110.719 179.018 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -117.43 104.42 11.08 Favored 'General case' 0 N--CA 1.496 1.848 0 N-CA-C 108.865 -0.791 . . . . 0.16 108.865 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.87 ' NH1' HG12 ' A' ' 28' ' ' VAL . 51.8 ttp180 -108.27 128.29 54.6 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 122.159 0.98 . . . . 3.19 112.104 -177.486 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 89.3 mt -95.99 127.5 48.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.782 -0.821 . . . . 0.16 108.782 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.582 ' OD2' ' NE2' ' A' ' 25' ' ' HIS . 67.1 t0 -163.74 115.33 1.39 Allowed 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 120.039 -0.664 . . . . 0.51 109.922 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.08 -10.0 12.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.136 -0.978 . . . . 2.09 109.773 -179.548 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 95.1 mtt180 -100.58 -2.84 31.85 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.89 -1.131 . . . . 2.94 110.554 -179.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 55.6 mt 59.02 -101.35 0.12 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.14 -0.975 . . . . 0.28 109.705 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 96.5 mt -101.49 124.45 55.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.343 -0.848 . . . . 0.26 109.263 179.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.582 ' NE2' ' OD2' ' A' ' 20' ' ' ASP . 5.8 p80 -150.23 140.07 21.83 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.876 -1.14 . . . . 0.51 110.006 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 54.96 -153.23 11.35 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.781 -1.328 . . . . 0.37 109.781 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -91.26 11.66 22.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.531 -0.982 . . . . 0.95 108.935 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.87 HG12 ' NH1' ' A' ' 18' ' ' ARG . 85.2 t -60.19 -44.58 95.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.516 -0.74 . . . . 0.37 109.585 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.46 -34.68 65.5 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 121.156 -0.965 . . . . 0.36 109.896 179.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.5 m -67.43 -53.91 24.92 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 119.862 -0.735 . . . . 0.35 109.917 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -64.22 -44.61 91.39 Favored 'General case' 0 N--CA 1.496 1.839 0 CA-C-O 121.364 0.602 . . . . 3.08 110.927 -178.102 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.472 ' CH2' ' ND2' ' A' ' 114' ' ' ASN . 24.3 m95 -67.09 -32.4 73.53 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.401 -0.812 . . . . 0.96 110.368 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.447 HG21 HG21 ' A' ' 66' ' ' VAL . 82.6 m -65.57 -45.96 81.28 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.814 -1.179 . . . . 0.32 110.034 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 81.6 tttt -69.11 -42.27 76.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.206 -0.934 . . . . 1.99 110.324 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -69.0 -39.25 79.43 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.949 -1.094 . . . . 2.52 109.471 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.417 ' OG1' ' O ' ' A' ' 32' ' ' TRP . 73.7 p -80.18 -0.46 36.23 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.101 -1.0 . . . . 0.35 109.64 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 51.54 47.7 24.32 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.939 -1.101 . . . . 2.01 108.447 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.434 ' CG1' ' O ' ' A' ' 40' ' ' ARG . 55.5 t -105.09 133.54 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.07 -1.019 . . . . 1.1 109.68 -178.679 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 95.3 p -110.58 -5.06 15.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 107.81 -1.181 . . . . 1.3 107.81 178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.434 ' O ' ' CG1' ' A' ' 38' ' ' VAL . 0.1 OUTLIER -137.18 140.37 41.75 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.86 0.838 . . . . 2.98 111.025 -179.201 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.8 mt -133.1 127.52 54.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.395 -0.965 . . . . 0.18 108.395 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.696 HD12 HG11 ' A' ' 90' ' ' VAL . 97.9 mt -116.42 129.67 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.279 -0.888 . . . . 0.15 109.653 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 53.5 t -99.63 129.18 50.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.879 -0.786 . . . . 0.34 108.879 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.0 t -111.91 103.97 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.578 -0.701 . . . . 0.23 109.6 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 42.0 t -167.28 124.65 1.22 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.112 -0.992 . . . . 1.29 108.969 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -72.87 -35.13 67.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.412 -0.805 . . . . 0.71 110.339 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.19 -44.67 87.68 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.277 -0.89 . . . . 2.19 109.767 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 79.3 t -70.49 -43.23 78.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.136 -0.977 . . . . 0.3 109.543 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.68 -25.83 60.82 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.384 -0.823 . . . . 0.24 109.117 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.64 -5.39 59.17 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.188 -0.945 . . . . 0.24 109.36 179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -102.92 96.0 6.53 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.015 -1.053 . . . . 0.33 109.386 179.255 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 17.5 p -65.73 -32.45 74.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.319 -0.863 . . . . 1.31 110.537 -179.608 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.56 -46.67 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.81 -1.181 . . . . 0.24 110.494 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 -64.56 -40.49 95.66 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.096 -1.002 . . . . 2.31 109.443 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 78.6 tttt -59.01 -42.39 90.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.218 -0.926 . . . . 1.74 109.646 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 97.8 m -61.6 -47.67 84.4 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 119.304 -0.958 . . . . 0.31 109.433 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.523 ' O ' HG22 ' A' ' 61' ' ' VAL . 56.0 mt -62.96 -43.58 98.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.159 -0.963 . . . . 0.41 110.602 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 82.2 mt -64.63 -41.29 96.25 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.782 -1.199 . . . . 0.34 109.502 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 34.0 p -69.28 -32.57 71.84 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.189 -0.945 . . . . 0.35 110.002 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 71.3 mt-30 -80.36 -15.82 55.97 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.601 -1.312 . . . . 2.02 110.853 -179.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.523 HG22 ' O ' ' A' ' 57' ' ' LEU . 20.4 m -109.04 17.37 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 120.884 -1.135 . . . . 0.4 109.082 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.18 124.63 84.71 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.314 -0.867 . . . . 0.34 109.095 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -44.9 146.03 2.64 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.905 1.737 . . . . 0.56 112.126 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -55.18 133.59 58.98 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 C-N-CA 122.137 1.891 . . . . 0.46 112.258 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.64 -7.65 47.37 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 110.162 -1.175 . . . . 0.23 110.162 178.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.447 HG21 HG21 ' A' ' 33' ' ' THR . 25.7 t -113.06 134.92 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -1.14 . . . . 0.59 109.277 -179.334 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.03 134.94 47.29 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.401 -0.812 . . . . 1.21 109.072 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -111.3 133.22 53.79 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.967 -1.123 . . . . 0.18 107.967 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -122.86 155.32 36.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.529 -0.732 . . . . 0.24 110.096 -179.059 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 46.6 t -127.47 118.09 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.892 -0.781 . . . . 0.18 108.892 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 m -139.23 165.38 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.497 -0.752 . . . . 0.16 109.703 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.453 ' OD1' ' N ' ' A' ' 72' ' ' ASP . 6.2 p-10 -94.96 167.77 11.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.4 -0.813 . . . . 1.11 109.186 178.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 76.0 t -56.79 -45.14 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.187 -0.945 . . . . 0.23 109.845 -177.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.826 ' O ' HG22 ' A' ' 77' ' ' ILE . . . -61.6 -42.52 98.99 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.982 -1.074 . . . . 0.21 109.616 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 72.1 tttt -73.18 -33.76 65.62 Favored 'General case' 0 C--N 1.294 -1.839 0 O-C-N 120.371 -1.456 . . . . 2.01 111.149 -178.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 12.7 tpt -62.04 -39.07 91.07 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.551 -1.343 . . . . 1.48 110.128 -179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.826 HG22 ' O ' ' A' ' 74' ' ' ALA . 16.6 tt -61.74 -36.71 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.262 -0.899 . . . . 0.51 108.719 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 15.1 mtt180 -72.45 -38.26 68.32 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.156 -0.965 . . . . 3.58 110.631 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 95.5 t -62.69 -42.31 95.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 120.947 -1.096 . . . . 0.23 108.051 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -67.35 -30.85 70.78 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.036 -1.04 . . . . 0.56 109.762 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -74.26 6.96 3.11 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.212 -0.93 . . . . 0.65 110.032 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 64.4 t-20 -109.41 112.89 58.86 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.195 -0.94 . . . . 0.6 109.558 179.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -60.98 -0.54 1.24 Allowed 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 121.707 1.605 . . . . 0.7 111.915 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -61.94 -22.95 66.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -0.958 . . . . 1.62 109.467 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -105.9 13.98 28.68 Favored 'General case' 0 N--CA 1.492 1.67 0 C-N-CA 119.657 -0.817 . . . . 0.77 109.144 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.409 ' C ' ' H ' ' A' ' 88' ' ' GLU . . . -52.92 134.9 37.3 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.026 -1.046 . . . . 0.25 110.622 -178.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 78.27 -33.21 1.78 Allowed Glycine 0 N--CA 1.487 2.063 0 N-CA-C 109.38 -1.488 . . . . 0.25 109.38 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLU . . . . . 0.409 ' H ' ' C ' ' A' ' 86' ' ' ALA . 26.1 tp10 -52.88 137.22 32.71 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.268 -1.137 . . . . 2.18 109.601 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 53.7 mtt180 -96.9 119.03 34.62 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.224 -0.923 . . . . 3.11 109.418 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.696 HG11 HD12 ' A' ' 42' ' ' ILE . 91.1 t -124.76 143.06 39.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 CA-C-O 121.885 0.85 . . . . 0.41 110.883 -177.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 12.8 ttp -102.53 135.15 44.67 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.368 -0.975 . . . . 1.57 108.368 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 61.0 mt -101.12 128.05 47.38 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.61 -0.836 . . . . 0.17 110.221 -178.331 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.402 ' HA ' HD23 ' A' ' 93' ' ' LEU . 94.9 mt -109.27 125.6 52.46 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.844 0.831 . . . . 0.52 109.016 179.173 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -126.39 161.88 26.84 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.645 0.736 . . . . 0.16 109.805 -178.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 69.3 p -108.93 -20.42 13.05 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.459 -0.941 . . . . 0.21 108.459 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ASN . . . . . 0.476 ' OD1' ' O ' ' A' ' 96' ' ' ASN . 20.5 p30 -150.89 141.6 14.76 Favored Pre-proline 0 N--CA 1.489 1.475 0 O-C-N 121.67 -0.644 . . . . 1.0 109.784 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -62.56 -12.62 29.01 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 122.498 2.132 . . . . 0.39 112.029 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 98.4 m -64.41 -42.79 95.86 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.394 -0.965 . . . . 0.27 108.394 177.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.452 ' O ' HD12 ' A' ' 103' ' ' LEU . 98.2 m-20 -68.24 -23.74 64.83 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.548 -0.72 . . . . 0.37 110.219 -179.542 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 99.6 t -72.29 -43.72 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.068 -1.02 . . . . 0.24 109.439 178.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -63.59 -35.01 79.11 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.409 -0.916 . . . . 1.94 108.799 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 89.7 mtt180 -62.95 -42.4 99.8 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.193 -1.003 . . . . 3.05 110.061 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.452 HD12 ' O ' ' A' ' 99' ' ' ASP . 3.2 mp -64.8 -40.17 94.79 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 117.783 -1.567 . . . . 1.17 108.913 179.064 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.578 ' CG2' HD12 ' A' ' 110' ' ' ILE . 83.4 t -61.57 -45.14 99.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 120.766 -1.209 . . . . 0.26 109.107 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -59.17 -30.06 67.9 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.97 -1.081 . . . . 2.44 109.533 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -76.42 2.99 55.84 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.886 -1.286 . . . . 0.24 109.886 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.53 15.16 47.92 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 110.154 -1.179 . . . . 0.23 110.154 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 97.4 t -78.11 138.56 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 107.185 -1.413 . . . . 0.22 107.185 177.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.928 ' HD2' HD22 ' A' ' 9' ' ' ASN . 56.1 tttt -95.62 120.95 36.76 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.249 -0.907 . . . . 2.99 111.369 -177.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.578 HD12 ' CG2' ' A' ' 104' ' ' VAL . 98.1 mt -129.81 124.96 59.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.375 -0.828 . . . . 0.17 108.804 178.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 37.5 p -92.45 -30.15 15.89 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.771 -1.206 . . . . 0.4 110.479 -178.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 22.0 m -156.58 151.19 25.71 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.008 -1.057 . . . . 0.16 109.986 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.2 t -122.92 134.46 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 N-CA-C 109.08 -0.711 . . . . 0.16 109.08 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ASN . . . . . 0.485 ' CG ' ' HE ' ' A' ' 154' ' ' ARG . 37.8 t30 -108.43 127.5 53.95 Favored 'General case' 0 N--CA 1.488 1.44 0 CA-C-O 121.687 0.756 . . . . 1.23 110.629 -178.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.585 HG21 ' SD ' ' A' ' 164' ' ' MET . 3.4 t -90.33 108.17 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 C-N-CA 119.955 -0.698 . . . . 0.16 109.195 179.383 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -81.05 -52.77 4.17 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.874 -1.29 . . . . 0.15 109.874 -179.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -174.18 153.29 16.39 Favored Glycine 0 N--CA 1.49 2.279 0 C-N-CA 118.785 -1.674 . . . . 0.16 111.266 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.447 ' HB2' ' H ' ' A' ' 132' ' ' SER . 98.6 mtp -143.39 117.97 9.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.671 -0.899 . . . . 0.2 109.823 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -52.07 129.07 26.45 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.343 -0.848 . . . . 0.25 109.492 -179.278 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.664 ' CD1' ' N ' ' A' ' 121' ' ' ARG . 11.9 t80 -71.12 161.1 31.69 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.306 -0.871 . . . . 0.45 109.463 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.664 ' N ' ' CD1' ' A' ' 120' ' ' PHE . 10.1 ttm180 -160.56 159.93 31.2 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.13 -0.981 . . . . 3.33 108.914 178.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 55.0 tt0 -65.74 138.58 58.04 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.883 -1.135 . . . . 2.11 110.725 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.74 -12.91 65.8 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.053 -1.619 . . . . 0.22 109.053 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -100.56 162.4 12.96 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.338 -1.095 . . . . 1.61 109.371 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.466 HG21 HG21 ' A' ' 171' ' ' ILE . 23.6 m -108.98 135.21 50.53 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.507 -0.923 . . . . 0.19 108.507 179.098 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -79.83 117.43 20.69 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 120.974 -1.079 . . . . 1.29 110.108 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.544 HG22 ' O ' ' A' ' 131' ' ' VAL . 26.7 m -96.68 -28.75 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 N-CA-C 108.942 -0.762 . . . . 0.45 108.942 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -139.04 -177.09 4.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.269 -0.894 . . . . 1.13 109.923 -179.505 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 65.2 m-20 -58.22 -29.73 65.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.535 -0.728 . . . . 2.36 110.864 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -145.5 24.38 1.4 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.793 -1.192 . . . . 0.24 109.775 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.544 ' O ' HG22 ' A' ' 127' ' ' VAL . 60.3 t -118.95 119.66 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 CA-C-O 121.968 0.889 . . . . 0.19 109.39 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.447 ' H ' ' HB2' ' A' ' 118' ' ' MET . 40.5 m -117.35 147.34 42.71 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.388 0.613 . . . . 0.4 109.404 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 12.7 m -135.99 137.96 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 CA-C-O 122.017 0.913 . . . . 0.19 110.746 -179.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ASP . . . . . 0.441 ' OD1' ' CG ' ' A' ' 137' ' ' ASP . 32.2 p-10 -104.58 171.2 7.46 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.115 -1.439 . . . . 0.57 107.115 178.001 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -57.68 -23.15 49.99 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.721 -1.237 . . . . 2.16 109.556 -179.104 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -79.52 -43.07 23.82 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.154 -0.966 . . . . 1.87 109.691 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ASP . . . . . 0.441 ' CG ' ' OD1' ' A' ' 134' ' ' ASP . 98.1 m-20 -63.72 -41.5 98.06 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.267 -0.895 . . . . 0.21 108.703 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 95.8 mt -62.13 -45.59 98.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 108.794 -0.817 . . . . 0.16 108.794 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -57.73 -38.36 75.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.939 -1.101 . . . . 2.3 110.503 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.59 -40.77 84.79 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.605 -1.31 . . . . 0.17 109.772 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -64.51 -40.11 95.03 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.37 -0.831 . . . . 0.2 110.019 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 71.3 mttt -63.78 -39.54 94.51 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.945 -1.097 . . . . 2.02 110.488 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 33.1 mttt -66.78 -41.19 88.08 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.044 -1.035 . . . . 1.79 110.14 -179.235 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 55.9 mt -62.75 -42.18 99.55 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.844 -1.169 . . . . 0.27 107.844 179.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ASN . . . . . 0.58 HD22 ' HG3' ' A' ' 165' ' ' MET . 35.7 t-20 -63.63 -40.24 96.37 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.275 -0.891 . . . . 1.22 109.458 179.119 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -62.61 -22.55 66.49 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.088 -1.008 . . . . 0.2 109.379 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 77.0 mtt-85 -88.54 7.32 33.71 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.051 -1.03 . . . . 2.49 109.674 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 82.38 12.6 80.26 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.801 -1.319 . . . . 0.18 109.801 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 96.0 mt -85.88 135.18 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.076 -1.25 . . . . 0.17 109.449 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -81.99 141.25 33.43 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.406 -0.809 . . . . 2.44 110.886 -179.245 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 61.0 mt -123.47 111.55 16.45 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.034 -0.728 . . . . 0.17 109.034 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -115.28 139.86 49.6 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.352 -0.842 . . . . 2.14 110.33 -179.174 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.606 ' CG2' ' SD ' ' A' ' 164' ' ' MET . 48.8 t -111.03 123.86 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 108.99 -0.745 . . . . 0.21 108.99 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.485 ' HE ' ' CG ' ' A' ' 114' ' ' ASN . 31.2 ptt180 -164.74 137.44 4.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.221 -0.924 . . . . 3.09 110.899 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -80.63 -45.29 17.51 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.233 -0.917 . . . . 1.8 109.776 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 25.6 m -129.74 154.05 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.152 -0.968 . . . . 0.35 109.015 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 4.2 p -65.26 -15.84 62.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.905 -1.122 . . . . 1.12 109.591 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 50.1 p -86.17 -9.11 57.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.014 -1.054 . . . . 0.53 109.528 -179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -92.59 150.27 39.5 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.167 -0.958 . . . . 0.45 109.497 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -55.65 141.03 84.49 Favored 'Trans proline' 0 N--CA 1.493 1.445 0 C-N-CA 121.772 1.648 . . . . 0.33 111.458 179.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 8.3 mttt -84.84 134.75 34.28 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.923 -1.11 . . . . 2.82 109.698 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 87.8 mt -114.77 153.31 30.57 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.51 -1.293 . . . . 0.22 107.51 178.089 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -90.34 130.97 36.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.662 -1.274 . . . . 2.08 109.538 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.606 ' SD ' ' CG2' ' A' ' 153' ' ' VAL . 8.0 tpt -56.78 -44.22 81.63 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.565 -0.709 . . . . 1.03 109.414 -178.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' MET . . . . . 0.58 ' HG3' HD22 ' A' ' 145' ' ' ASN . 93.7 mmm -60.76 -41.16 94.89 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.109 -0.994 . . . . 1.48 109.649 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -60.91 -43.66 98.23 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.414 -0.804 . . . . 0.28 110.001 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 93.0 mt -65.61 -41.79 92.33 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.213 -0.929 . . . . 0.24 109.5 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 95.9 mt -75.99 -25.08 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.448 -0.783 . . . . 0.22 109.544 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -71.56 -30.54 66.0 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.279 -1.513 . . . . 1.34 109.684 179.409 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 94.4 mttt -84.23 -6.25 59.37 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 119.197 -1.001 . . . . 2.13 109.37 -179.438 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' ILE . . . . . 0.515 ' CD1' HG12 ' A' ' 127' ' ' VAL . 97.1 mt -109.07 -66.1 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 105.842 -1.91 . . . . 0.87 105.842 176.391 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 172' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -81.97 140.69 33.85 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 106.803 -1.554 . . . . 2.1 106.803 177.401 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' LYS . . . . . 0.826 ' HZ2' ' C ' ' A' ' 173' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.286 -2.167 0 C-N-CA 119.44 -0.904 . . . . 6.78 108.723 -179.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.643 HD21 ' HZ2' ' A' ' 109' ' ' LYS . 6.9 m-20 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.475 -0.565 . . . . 5.5199999999999996 109.475 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -81.46 36.01 0.42 Allowed 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.435 -0.95 . . . . 3.8599999999999999 108.435 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.422 ' H ' ' C ' ' A' ' 9' ' ' ASN . 63.7 m-85 -118.22 -134.77 0.33 Allowed 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.751 -0.593 . . . . 1.51 109.505 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.419 ' SD ' ' HB ' ' A' ' 90' ' ' VAL . 6.6 ttm -63.63 150.09 45.0 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.04 -1.038 . . . . 2.4399999999999999 110.73 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 91.0 t -112.02 116.07 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.462 -0.774 . . . . 0.33000000000000002 109.029 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 98.1 mt -73.6 104.26 2.4 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.355 -0.841 . . . . 0.22 108.955 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.56 -34.56 79.14 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.933 -1.667 . . . . 0.19 108.933 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 39.1 tp -171.94 147.53 2.17 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 118.845 -1.142 . . . . 0.32000000000000001 110.719 179.018 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -117.43 104.42 11.08 Favored 'General case' 0 N--CA 1.496 1.848 0 N-CA-C 108.865 -0.791 . . . . 0.16 108.865 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.87 ' NH1' HG12 ' A' ' 28' ' ' VAL . 51.8 ttp180 -108.27 128.29 54.6 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 122.159 0.98 . . . . 3.1899999999999999 112.104 -177.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 89.3 mt -95.99 127.5 48.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.782 -0.821 . . . . 0.16 108.782 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.582 ' OD2' ' NE2' ' A' ' 25' ' ' HIS . 67.1 t0 -163.74 115.33 1.39 Allowed 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 120.039 -0.664 . . . . 0.51000000000000001 109.922 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.08 -10.0 12.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.136 -0.978 . . . . 2.0899999999999999 109.773 -179.548 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 95.1 mtt180 -100.58 -2.84 31.85 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.89 -1.131 . . . . 2.9399999999999999 110.554 -179.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 55.6 mt 59.02 -101.35 0.12 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.14 -0.975 . . . . 0.28000000000000003 109.705 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 96.5 mt -101.49 124.45 55.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.343 -0.848 . . . . 0.26000000000000001 109.263 179.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.582 ' NE2' ' OD2' ' A' ' 20' ' ' ASP . 5.8 p80 -150.23 140.07 21.83 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.876 -1.14 . . . . 0.51000000000000001 110.006 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 54.96 -153.23 11.35 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.781 -1.328 . . . . 0.37 109.781 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -91.26 11.66 22.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.531 -0.982 . . . . 0.94999999999999996 108.935 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.87 HG12 ' NH1' ' A' ' 18' ' ' ARG . 85.2 t -60.19 -44.58 95.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.516 -0.74 . . . . 0.37 109.585 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.46 -34.68 65.5 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 121.156 -0.965 . . . . 0.35999999999999999 109.896 179.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.5 m -67.43 -53.91 24.92 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 119.862 -0.735 . . . . 0.34999999999999998 109.917 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -64.22 -44.61 91.39 Favored 'General case' 0 N--CA 1.496 1.839 0 CA-C-O 121.364 0.602 . . . . 3.0800000000000001 110.927 -178.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.472 ' CH2' ' ND2' ' A' ' 114' ' ' ASN . 24.3 m95 -67.09 -32.4 73.53 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.401 -0.812 . . . . 0.95999999999999996 110.368 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.447 HG21 HG21 ' A' ' 66' ' ' VAL . 82.6 m -65.57 -45.96 81.28 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.814 -1.179 . . . . 0.32000000000000001 110.034 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 81.6 tttt -69.11 -42.27 76.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.206 -0.934 . . . . 1.99 110.324 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -69.0 -39.25 79.43 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.949 -1.094 . . . . 2.52 109.471 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.417 ' OG1' ' O ' ' A' ' 32' ' ' TRP . 73.7 p -80.18 -0.46 36.23 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.101 -1.0 . . . . 0.34999999999999998 109.64 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 51.54 47.7 24.32 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.939 -1.101 . . . . 2.0099999999999998 108.447 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.434 ' CG1' ' O ' ' A' ' 40' ' ' ARG . 55.5 t -105.09 133.54 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.07 -1.019 . . . . 1.1000000000000001 109.68 -178.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 95.3 p -110.58 -5.06 15.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 107.81 -1.181 . . . . 1.3 107.81 178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.434 ' O ' ' CG1' ' A' ' 38' ' ' VAL . 0.1 OUTLIER -137.18 140.37 41.75 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.86 0.838 . . . . 2.98 111.025 -179.201 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.8 mt -133.1 127.52 54.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.395 -0.965 . . . . 0.17999999999999999 108.395 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.696 HD12 HG11 ' A' ' 90' ' ' VAL . 97.9 mt -116.42 129.67 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.279 -0.888 . . . . 0.14999999999999999 109.653 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 53.5 t -99.63 129.18 50.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.879 -0.786 . . . . 0.34000000000000002 108.879 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.0 t -111.91 103.97 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.578 -0.701 . . . . 0.23000000000000001 109.6 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 42.0 t -167.28 124.65 1.22 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.112 -0.992 . . . . 1.29 108.969 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -72.87 -35.13 67.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.412 -0.805 . . . . 0.70999999999999996 110.339 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.19 -44.67 87.68 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.277 -0.89 . . . . 2.1899999999999999 109.767 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 79.3 t -70.49 -43.23 78.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.136 -0.977 . . . . 0.29999999999999999 109.543 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.68 -25.83 60.82 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.384 -0.823 . . . . 0.23999999999999999 109.117 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.64 -5.39 59.17 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.188 -0.945 . . . . 0.23999999999999999 109.36 179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -102.92 96.0 6.53 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.015 -1.053 . . . . 0.33000000000000002 109.386 179.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 17.5 p -65.73 -32.45 74.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.319 -0.863 . . . . 1.3100000000000001 110.537 -179.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.56 -46.67 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.81 -1.181 . . . . 0.23999999999999999 110.494 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 -64.56 -40.49 95.66 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.096 -1.002 . . . . 2.3100000000000001 109.443 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 78.6 tttt -59.01 -42.39 90.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.218 -0.926 . . . . 1.74 109.646 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 97.8 m -61.6 -47.67 84.4 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 119.304 -0.958 . . . . 0.31 109.433 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.523 ' O ' HG22 ' A' ' 61' ' ' VAL . 56.0 mt -62.96 -43.58 98.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.159 -0.963 . . . . 0.40999999999999998 110.602 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 82.2 mt -64.63 -41.29 96.25 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.782 -1.199 . . . . 0.34000000000000002 109.502 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 34.0 p -69.28 -32.57 71.84 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.189 -0.945 . . . . 0.34999999999999998 110.002 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 71.3 mt-30 -80.36 -15.82 55.97 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.601 -1.312 . . . . 2.02 110.853 -179.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.523 HG22 ' O ' ' A' ' 57' ' ' LEU . 20.4 m -109.04 17.37 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 120.884 -1.135 . . . . 0.40000000000000002 109.082 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.18 124.63 84.71 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.314 -0.867 . . . . 0.34000000000000002 109.095 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -44.9 146.03 2.64 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.905 1.737 . . . . 0.56000000000000005 112.126 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -55.18 133.59 58.98 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 C-N-CA 122.137 1.891 . . . . 0.46000000000000002 112.258 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.64 -7.65 47.37 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 110.162 -1.175 . . . . 0.23000000000000001 110.162 178.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.447 HG21 HG21 ' A' ' 33' ' ' THR . 25.7 t -113.06 134.92 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -1.14 . . . . 0.58999999999999997 109.277 -179.334 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.03 134.94 47.29 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.401 -0.812 . . . . 1.21 109.072 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -111.3 133.22 53.79 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.967 -1.123 . . . . 0.17999999999999999 107.967 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -122.86 155.32 36.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.529 -0.732 . . . . 0.23999999999999999 110.096 -179.059 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 46.6 t -127.47 118.09 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.892 -0.781 . . . . 0.17999999999999999 108.892 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 m -139.23 165.38 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.497 -0.752 . . . . 0.16 109.703 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.453 ' OD1' ' N ' ' A' ' 72' ' ' ASP . 6.2 p-10 -94.96 167.77 11.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.4 -0.813 . . . . 1.1100000000000001 109.186 178.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 76.0 t -56.79 -45.14 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.187 -0.945 . . . . 0.23000000000000001 109.845 -177.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.826 ' O ' HG22 ' A' ' 77' ' ' ILE . . . -61.6 -42.52 98.99 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.982 -1.074 . . . . 0.20999999999999999 109.616 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 72.1 tttt -73.18 -33.76 65.62 Favored 'General case' 0 C--N 1.294 -1.839 0 O-C-N 120.371 -1.456 . . . . 2.0099999999999998 111.149 -178.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 12.7 tpt -62.04 -39.07 91.07 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.551 -1.343 . . . . 1.48 110.128 -179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.826 HG22 ' O ' ' A' ' 74' ' ' ALA . 16.6 tt -61.74 -36.71 75.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.262 -0.899 . . . . 0.51000000000000001 108.719 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 15.1 mtt180 -72.45 -38.26 68.32 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.156 -0.965 . . . . 3.5800000000000001 110.631 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 95.5 t -62.69 -42.31 95.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 120.947 -1.096 . . . . 0.23000000000000001 108.051 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -67.35 -30.85 70.78 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.036 -1.04 . . . . 0.56000000000000005 109.762 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -74.26 6.96 3.11 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.212 -0.93 . . . . 0.65000000000000002 110.032 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 64.4 t-20 -109.41 112.89 58.86 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.195 -0.94 . . . . 0.59999999999999998 109.558 179.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -60.98 -0.54 1.24 Allowed 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 121.707 1.605 . . . . 0.69999999999999996 111.915 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -61.94 -22.95 66.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -0.958 . . . . 1.6200000000000001 109.467 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -105.9 13.98 28.68 Favored 'General case' 0 N--CA 1.492 1.67 0 C-N-CA 119.657 -0.817 . . . . 0.77000000000000002 109.144 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.409 ' C ' ' H ' ' A' ' 88' ' ' GLU . . . -52.92 134.9 37.3 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.026 -1.046 . . . . 0.25 110.622 -178.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 78.27 -33.21 1.78 Allowed Glycine 0 N--CA 1.487 2.063 0 N-CA-C 109.38 -1.488 . . . . 0.25 109.38 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . 0.409 ' H ' ' C ' ' A' ' 86' ' ' ALA . 26.1 tp10 -52.88 137.22 32.71 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.268 -1.137 . . . . 2.1800000000000002 109.601 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 53.7 mtt180 -96.9 119.03 34.62 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.224 -0.923 . . . . 3.1099999999999999 109.418 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.696 HG11 HD12 ' A' ' 42' ' ' ILE . 91.1 t -124.76 143.06 39.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 CA-C-O 121.885 0.85 . . . . 0.40999999999999998 110.883 -177.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 12.8 ttp -102.53 135.15 44.67 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.368 -0.975 . . . . 1.5700000000000001 108.368 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 61.0 mt -101.12 128.05 47.38 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.61 -0.836 . . . . 0.17000000000000001 110.221 -178.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.402 ' HA ' HD23 ' A' ' 93' ' ' LEU . 94.9 mt -109.27 125.6 52.46 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.844 0.831 . . . . 0.52000000000000002 109.016 179.173 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -126.39 161.88 26.84 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.645 0.736 . . . . 0.16 109.805 -178.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 69.3 p -108.93 -20.42 13.05 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.459 -0.941 . . . . 0.20999999999999999 108.459 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . 0.476 ' O ' ' OD1' ' A' ' 96' ' ' ASN . 20.5 p30 -150.89 141.6 14.76 Favored Pre-proline 0 N--CA 1.489 1.475 0 O-C-N 121.67 -0.644 . . . . 1.0 109.784 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -62.56 -12.62 29.01 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 122.498 2.132 . . . . 0.39000000000000001 112.029 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 98.4 m -64.41 -42.79 95.86 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.394 -0.965 . . . . 0.27000000000000002 108.394 177.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.452 ' O ' HD12 ' A' ' 103' ' ' LEU . 98.2 m-20 -68.24 -23.74 64.83 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.548 -0.72 . . . . 0.37 110.219 -179.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 99.6 t -72.29 -43.72 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.068 -1.02 . . . . 0.23999999999999999 109.439 178.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -63.59 -35.01 79.11 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.409 -0.916 . . . . 1.9399999999999999 108.799 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 89.7 mtt180 -62.95 -42.4 99.8 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.193 -1.003 . . . . 3.0499999999999998 110.061 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.452 HD12 ' O ' ' A' ' 99' ' ' ASP . 3.2 mp -64.8 -40.17 94.79 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 117.783 -1.567 . . . . 1.1699999999999999 108.913 179.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.578 ' CG2' HD12 ' A' ' 110' ' ' ILE . 83.4 t -61.57 -45.14 99.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 120.766 -1.209 . . . . 0.26000000000000001 109.107 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -59.17 -30.06 67.9 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.97 -1.081 . . . . 2.4399999999999999 109.533 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -76.42 2.99 55.84 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.886 -1.286 . . . . 0.23999999999999999 109.886 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.53 15.16 47.92 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 110.154 -1.179 . . . . 0.23000000000000001 110.154 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 97.4 t -78.11 138.56 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 107.185 -1.413 . . . . 0.22 107.185 177.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.643 ' HZ2' HD21 ' A' ' 9' ' ' ASN . 56.1 tttt -95.62 120.95 36.76 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.249 -0.907 . . . . 2.9900000000000002 111.369 -177.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.578 HD12 ' CG2' ' A' ' 104' ' ' VAL . 98.1 mt -129.81 124.96 59.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.375 -0.828 . . . . 0.17000000000000001 108.804 178.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 37.5 p -92.45 -30.15 15.89 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.771 -1.206 . . . . 0.40000000000000002 110.479 -178.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 22.0 m -156.58 151.19 25.71 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.008 -1.057 . . . . 0.16 109.986 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.2 t -122.92 134.46 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 N-CA-C 109.08 -0.711 . . . . 0.16 109.08 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . 0.485 ' CG ' ' HE ' ' A' ' 154' ' ' ARG . 37.8 t30 -108.43 127.5 53.95 Favored 'General case' 0 N--CA 1.488 1.44 0 CA-C-O 121.687 0.756 . . . . 1.23 110.629 -178.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.585 HG21 ' SD ' ' A' ' 164' ' ' MET . 3.4 t -90.33 108.17 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 C-N-CA 119.955 -0.698 . . . . 0.16 109.195 179.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -81.05 -52.77 4.17 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.874 -1.29 . . . . 0.14999999999999999 109.874 -179.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -174.18 153.29 16.39 Favored Glycine 0 N--CA 1.49 2.279 0 C-N-CA 118.785 -1.674 . . . . 0.16 111.266 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.447 ' HB2' ' H ' ' A' ' 132' ' ' SER . 98.6 mtp -143.39 117.97 9.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.671 -0.899 . . . . 0.20000000000000001 109.823 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -52.07 129.07 26.45 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.343 -0.848 . . . . 0.25 109.492 -179.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.664 ' CD1' ' N ' ' A' ' 121' ' ' ARG . 11.9 t80 -71.12 161.1 31.69 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.306 -0.871 . . . . 0.45000000000000001 109.463 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.664 ' N ' ' CD1' ' A' ' 120' ' ' PHE . 10.1 ttm180 -160.56 159.93 31.2 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.13 -0.981 . . . . 3.3300000000000001 108.914 178.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 55.0 tt0 -65.74 138.58 58.04 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.883 -1.135 . . . . 2.1099999999999999 110.725 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.74 -12.91 65.8 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.053 -1.619 . . . . 0.22 109.053 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -100.56 162.4 12.96 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.338 -1.095 . . . . 1.6100000000000001 109.371 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.466 HG21 HG21 ' A' ' 171' ' ' ILE . 23.6 m -108.98 135.21 50.53 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.507 -0.923 . . . . 0.19 108.507 179.098 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -79.83 117.43 20.69 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 120.974 -1.079 . . . . 1.29 110.108 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.544 HG22 ' O ' ' A' ' 131' ' ' VAL . 26.7 m -96.68 -28.75 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 N-CA-C 108.942 -0.762 . . . . 0.45000000000000001 108.942 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -139.04 -177.09 4.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.269 -0.894 . . . . 1.1299999999999999 109.923 -179.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 65.2 m-20 -58.22 -29.73 65.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.535 -0.728 . . . . 2.3599999999999999 110.864 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -145.5 24.38 1.4 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.793 -1.192 . . . . 0.23999999999999999 109.775 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.544 ' O ' HG22 ' A' ' 127' ' ' VAL . 60.3 t -118.95 119.66 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 CA-C-O 121.968 0.889 . . . . 0.19 109.39 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.447 ' H ' ' HB2' ' A' ' 118' ' ' MET . 40.5 m -117.35 147.34 42.71 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.388 0.613 . . . . 0.40000000000000002 109.404 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 12.7 m -135.99 137.96 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 CA-C-O 122.017 0.913 . . . . 0.19 110.746 -179.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . 0.441 ' OD1' ' CG ' ' A' ' 137' ' ' ASP . 32.2 p-10 -104.58 171.2 7.46 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.115 -1.439 . . . . 0.56999999999999995 107.115 178.001 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -57.68 -23.15 49.99 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.721 -1.237 . . . . 2.1600000000000001 109.556 -179.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -79.52 -43.07 23.82 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.154 -0.966 . . . . 1.8700000000000001 109.691 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . 0.441 ' CG ' ' OD1' ' A' ' 134' ' ' ASP . 98.1 m-20 -63.72 -41.5 98.06 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.267 -0.895 . . . . 0.20999999999999999 108.703 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 95.8 mt -62.13 -45.59 98.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 108.794 -0.817 . . . . 0.16 108.794 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -57.73 -38.36 75.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.939 -1.101 . . . . 2.2999999999999998 110.503 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.59 -40.77 84.79 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.605 -1.31 . . . . 0.17000000000000001 109.772 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -64.51 -40.11 95.03 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.37 -0.831 . . . . 0.20000000000000001 110.019 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 71.3 mttt -63.78 -39.54 94.51 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.945 -1.097 . . . . 2.02 110.488 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 33.1 mttt -66.78 -41.19 88.08 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.044 -1.035 . . . . 1.79 110.14 -179.235 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 55.9 mt -62.75 -42.18 99.55 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.844 -1.169 . . . . 0.27000000000000002 107.844 179.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . 0.58 HD22 ' HG3' ' A' ' 165' ' ' MET . 35.7 t-20 -63.63 -40.24 96.37 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.275 -0.891 . . . . 1.22 109.458 179.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -62.61 -22.55 66.49 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.088 -1.008 . . . . 0.20000000000000001 109.379 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 77.0 mtt-85 -88.54 7.32 33.71 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.051 -1.03 . . . . 2.4900000000000002 109.674 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 82.38 12.6 80.26 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.801 -1.319 . . . . 0.17999999999999999 109.801 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 96.0 mt -85.88 135.18 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.076 -1.25 . . . . 0.17000000000000001 109.449 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -81.99 141.25 33.43 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.406 -0.809 . . . . 2.4399999999999999 110.886 -179.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 61.0 mt -123.47 111.55 16.45 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.034 -0.728 . . . . 0.17000000000000001 109.034 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -115.28 139.86 49.6 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.352 -0.842 . . . . 2.1400000000000001 110.33 -179.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.606 ' CG2' ' SD ' ' A' ' 164' ' ' MET . 48.8 t -111.03 123.86 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 108.99 -0.745 . . . . 0.20999999999999999 108.99 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.485 ' HE ' ' CG ' ' A' ' 114' ' ' ASN . 31.2 ptt180 -164.74 137.44 4.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.221 -0.924 . . . . 3.0899999999999999 110.899 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -80.63 -45.29 17.51 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.233 -0.917 . . . . 1.8 109.776 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 25.6 m -129.74 154.05 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.152 -0.968 . . . . 0.34999999999999998 109.015 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 4.2 p -65.26 -15.84 62.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.905 -1.122 . . . . 1.1200000000000001 109.591 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 50.1 p -86.17 -9.11 57.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.014 -1.054 . . . . 0.53000000000000003 109.528 -179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -92.59 150.27 39.5 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.167 -0.958 . . . . 0.45000000000000001 109.497 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -55.65 141.03 84.49 Favored 'Trans proline' 0 N--CA 1.493 1.445 0 C-N-CA 121.772 1.648 . . . . 0.33000000000000002 111.458 179.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 8.3 mttt -84.84 134.75 34.28 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.923 -1.11 . . . . 2.8199999999999998 109.698 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 87.8 mt -114.77 153.31 30.57 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.51 -1.293 . . . . 0.22 107.51 178.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -90.34 130.97 36.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.662 -1.274 . . . . 2.0800000000000001 109.538 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.606 ' SD ' ' CG2' ' A' ' 153' ' ' VAL . 8.0 tpt -56.78 -44.22 81.63 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.565 -0.709 . . . . 1.03 109.414 -178.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' MET . . . . . 0.58 ' HG3' HD22 ' A' ' 145' ' ' ASN . 93.7 mmm -60.76 -41.16 94.89 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.109 -0.994 . . . . 1.48 109.649 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -60.91 -43.66 98.23 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.414 -0.804 . . . . 0.28000000000000003 110.001 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 93.0 mt -65.61 -41.79 92.33 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.213 -0.929 . . . . 0.23999999999999999 109.5 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 95.9 mt -75.99 -25.08 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.448 -0.783 . . . . 0.22 109.544 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -71.56 -30.54 66.0 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.279 -1.513 . . . . 1.3400000000000001 109.684 179.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 94.4 mttt -84.23 -6.25 59.37 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 119.197 -1.001 . . . . 2.1299999999999999 109.37 -179.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' ILE . . . . . 0.515 ' CD1' HG12 ' A' ' 127' ' ' VAL . 97.1 mt -109.07 -66.1 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 105.842 -1.91 . . . . 0.87 105.842 176.391 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -81.97 140.69 33.85 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 106.803 -1.554 . . . . 2.1000000000000001 106.803 177.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . 0.826 ' HZ2' ' C ' ' A' ' 173' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.286 -2.167 0 C-N-CA 119.44 -0.904 . . . . 6.7800000000000002 108.723 -179.582 . . . . . . . . 2 2 . 1 stop_ save_